What is the recommended follow-up for a thyroid nodule with a Bethesda (Bethesda System for Reporting Thyroid Cytopathology) category 2 diagnosis, with an ultrasound showing no change in size after 6 months?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a thyroid nodule that was biopsied and classified as Bethesda category 2 (benign) with follow-up ultrasound at 6 months showing similar size, routine clinical surveillance is recommended, with another follow-up ultrasound in 12-24 months to ensure continued stability, as supported by the American College of Radiology guidelines 1. This approach prioritizes the patient's quality of life and minimizes unnecessary interventions, given the very low risk of malignancy (less than 3%) in Bethesda 2 nodules. The stability in size on follow-up ultrasound further confirms the benign nature of the nodule. Key considerations in managing thyroid nodules include:

  • The role of imaging in diagnosing and characterizing thyroid findings, as outlined in the ACR Appropriateness Criteria for thyroid disease 1.
  • The importance of molecular testing for differentiated thyroid cancer (DTC), as discussed in the NCCN Guidelines for Thyroid Carcinoma 1.
  • The need for individualized management based on the type of thyroid cancer, patient factors, and clinical presentation. However, if the patient develops concerning symptoms such as difficulty swallowing, voice changes, or if the nodule significantly increases in size (generally more than 20% increase in at least two dimensions), earlier reassessment would be warranted. No medication is typically required for benign, stable thyroid nodules unless there is associated thyroid dysfunction. Overall, the management of thyroid nodules should balance the risks and benefits of intervention, prioritizing the patient's morbidity, mortality, and quality of life.

From the Research

Thyroid Nodule Biopsy Recommendations

  • For thyroid nodules biopsied with a Bethesda 2 category, the recommendation is to perform a follow-up ultrasound in 6-12 months to assess for any changes in size [ 2 ].
  • If the nodule size remains similar after 6 months, the risk of malignancy is relatively low, with a reported incidence of 1.53% [ 2 ].
  • However, it is essential to continue monitoring the nodule with regular ultrasound follow-ups to detect any potential changes [ 3 ].

Ultrasound Follow-up Intervals

  • A study published in 2018 found that repeat US-FNA for initially non-diagnostic thyroid nodules can be performed at a six-month interval after the initial procedure without tumor progression [ 3 ].
  • Another study from 2022 suggested that the combined use of TIRADS and BETHESDA categories can efficiently provide accurate results for making preoperative diagnoses of thyroid nodules and determining the risk of malignancy [ 4 ].

Malignancy Risk

  • The malignancy rate for Bethesda 2 category nodules is relatively low, with reported rates ranging from 1.53% to 15% [ 2, 5 ].
  • However, it is crucial to continue monitoring the nodule with regular ultrasound follow-ups to detect any potential changes and assess the risk of malignancy [ 3 ].

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cancer rate of Bethesda category II thyroid nodules.

Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.